Business Context and Reporting Period
This Form 8-K was filed by Cardio Diagnostics Holdings, Inc. on January 4, 2024. The report details the termination of a material definitive agreement with YA II PN, Ltd. ("Yorkville"), an affiliate of Yorkville Advisors Global, LP.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, or operating margins. The financial data presented relates specifically to the terminated debt agreement:
- Agreement Capacity: Up to $11.2 million in convertible debentures.
- First Convertible Debenture: Principal amount of $5.0 million (purchase price $4.5 million); fully repaid as of the filing date.
- Second Convertible Debenture: Principal amount of $6.2 million (purchase price $5.58 million); obligation terminated.
- Outstanding Borrowings: None at the time of termination.
- Termination Fees: None due by either party.
Material Changes
The primary material change is the mutual termination of the Securities Purchase Agreement dated March 8, 2023. Consequently, the Company's obligation to issue the Second Convertible Debenture and Yorkville's obligation to purchase it have been nullified. There are no outstanding borrowings or shares to be issued under this agreement.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the context of the agreement termination. The document confirms that the termination was executed by mutual consent with no financial penalties or outstanding obligations remaining.
Investor Verification Checklist
- Confirm the full repayment status of the $5.0 million First Convertible Debenture.
- Verify that no other outstanding debt facilities or convertible instruments exist with Yorkville.
- Review the Company's current liquidity position in light of the terminated $6.2 million funding option.
- Check for any subsequent filings regarding new financing arrangements to replace the terminated agreement.